Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13459
UPID:
MYO9B_HUMAN
Alternative names:
Unconventional myosin-9b
Alternative UPACC:
Q13459; O75314; Q9NUJ2; Q9UHN0
Background:
Unconventional myosin-IXb, encoded by the gene with accession number Q13459, is an actin-based motor molecule with ATPase activity, crucial for intracellular movements. It binds actin with high affinity, a process modulated by ATP and calcium ions. Additionally, it serves as a GTPase activator for RHOA, influencing cell migration through its interaction with the SLIT2 receptor ROBO1, which regulates RHOA GTPase activity and impacts active RHOA levels.
Therapeutic significance:
Unconventional myosin-IXb's involvement in Celiac disease 4, a chronic disorder triggered by gluten intolerance leading to immune-mediated enteropathy, highlights its potential as a therapeutic target. Understanding the role of Unconventional myosin-IXb could open doors to potential therapeutic strategies.